article thumbnail

8 Ways to Enhance the Patient Experience & Drive Leads with QR Codes

Healthcare Success

In this blog post, you’ll learn: Why QR codes have made a comeback, When to use them, And, 8 ways to improve the patient experience and drive leads with QR codes. . Suddenly the safety of contactless, hygienic interactions became a necessity. 8 Ways to Improve the Patient Experience & Drive Leads with QR Codes.

Leads 112
article thumbnail

8 Ways to Enhance the Patient Experience & Drive Leads with QR Codes

Healthcare Success

In this blog post, you’ll learn: Why QR codes have made a comeback, When to use them, And, 8 ways to improve the patient experience and drive leads with QR codes. . Suddenly the safety of contactless, hygienic interactions became a necessity. 8 Ways to Improve the Patient Experience & Drive Leads with QR Codes.

Leads 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

MHRA approves biosimilar for vision disorders in Great Britain

European Pharmaceutical Review

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for Ximluci ® (ranibizumab), a biosimilar referencing Lucentis®, to help treat a leading cause of blindness globally. First bispecific antibody approved in EU to combat leading causes of vision loss.

article thumbnail

Immunotherapy to become standard treatment for infants with ALL

European Pharmaceutical Review

“This is the first time that we tested blinatumomab as a first-line treatment, and for the first time in such young children,” stated Dr Inge van der Sluis, study lead and paediatric oncologist and clinical pharmacologist at the Princess Máxima Center for paediatric oncology in the Netherlands.

Safety 98
article thumbnail

PhRMA lies to protect pharma profits

World of DTC Marketing

He leads the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital in Boston. Data were mainly accessible for smaller firms, products in some therapeutic regions, orphan drugs, first-in-class drugs, therapeutic agents that received accelerated approval, and products between 2014 and 2018.

Pharma 255
article thumbnail

Brii Bio acquires Vir’s antibody rights for Hepatitis B in Greater China

Pharmaceutical Technology

The companies signed a partnership, option and license agreement in May 2018 under which Brii Bio gained the option for the acquisition of exclusive rights to some programmes of Vir in Greater China.

Safety 111
article thumbnail

Activ Surgical Secures CE Mark Approval for ActivSight™ Intelligent Light

Legacy MEDSearch

With ActivSight, surgeons can access critical intraoperative visual data as augmented reality overlays, helping to increase surgical outcomes and patient safety. “As We believe ActivSight will be a game-changer in the operating room by revolutionizing surgical vision and, ultimately, improving surgical care and patient safety.